BIO-TECHNE Corp — Director's Dealing 2015

Aug 11, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2015-08-07

Reporting Person: Eansor Norman David (SVP - Novus Biologicals)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-08-07	Stock Option (Right to Buy)	$108.49	A	12500	Acquired	2022-08-07	Common Stock (12500)	Direct
2015-08-07	Stock Option (Right to Buy)	$108.49	A	6250	Acquired	2022-08-07	Common Stock (6250)	Direct
2015-08-07	Restricted Stock Units	$	A	1000	Acquired		Common Stock (1000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4469	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$94.35	2021-08-12	Common Stock (15000)	15000	Direct

Footnotes

F1: Includes 3,333 shares of restricted stock units that vest 1,667 shares on 7/1/16 and 1,666 shares on 7/1/17 (previously reported on Table II).

F2: 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

F3: 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F5: Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.